Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Budesonide Stories

2014-03-25 00:21:44

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/s3kv36/investigation) has announced the addition of the "Investigation Report on China Budesonide Market" [http://www.researchandmarkets.com/research/s3kv36/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Asthma and allergic rhinitis are both very common diseases in the world today. As the global atmosphere...

2013-05-13 16:27:10

WILMINGTON, Del., May 13, 2013 /PRNewswire/ -- Approximately 25 million Americans suffer from asthma, which accounts for more than 3300 deaths each year. AstraZeneca (NYSE: AZN) is urging Americans to embrace National Asthma & Allergy Awareness Month this May by taking proactive steps to gain control of their asthma and learn more about how it may be impacting their lives. To view the multimedia assets associated with this release, please click:...

2012-08-01 02:28:41

PARSIPPANY, N.J., Aug. 1, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Budesonide Inhalation Suspension 0.25mg/2mL and 0.5mg/2mL Unit-dose ampules, the generic equivalent to AstraZeneca's Pulmicort RESPULES(®). Watson is currently involved in patent litigation with...

2011-12-22 17:00:00

EXTON, Pa. and SAN DIEGO, Dec. 22, 2011 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced that it has entered into an exclusive option to acquire Meritage Pharma, Inc., a private company based in San Diego, CA focused on developing oral budesonide suspension (OBS) as a treatment for eosinophilic esophagitis (EoE), a chronic inflammatory disorder of the esophagus. ViroPharma has paid an initial $7.5 million, and has agreed to provide Meritage up to an...

2011-06-23 19:01:00

PITTSBURGH, June 23, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. District Court for the District of Delaware has found after trial that Mylan subsidiary Mylan Pharmaceuticals Inc. does not infringe the asserted claims of U.S. Patent No. 5,643,602 with its Abbreviated New Drug Application (ANDA) for Budesonide Capsules, 3 mg (Enteric Coated), the generic version of AstraZeneca's Entocort EC® capsules, a treatment for Crohn's disease....

2011-05-10 08:00:00

CHICAGO, May 10, 2011 /PRNewswire/ -- Meritage Pharma, Inc. announced today its proprietary oral budesonide suspension (OBS) met the primary endpoint of reduction of esophageal eosinophilia and symptoms in a Phase 2b dose-ranging clinical trial in pediatric patients with eosinophilic esophagitis (EoE), an allergic inflammatory condition of the esophagus. Results from the Pediatric Eosinophilic Esophagitis Research (PEER) study were presented by principal investigators at Digestive Disease...

2011-03-01 08:00:00

SAN DIEGO, March 1, 2011 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today highlighted its financial results and product development progress for the year ended December 31, 2010. "Prometheus had another record year in 2010, our 14th consecutive year of sales growth," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "In addition, we made significant progress advancing a number of internal development programs,...

2010-11-30 15:34:00

SAN DIEGO, Nov. 30, 2010 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today that it has extended its distribution agreement with AstraZeneca LP for the exclusive marketing, sales and distribution of ENTOCORT® EC (budesonide) Capsules in the United States until December 31, 2011. ENTOCORT EC is the only FDA-approved drug for the induction and maintenance of clinical remission in mild to moderate Crohn's disease...

2010-11-02 07:37:00

WILMINGTON, Del., Nov. 2, 2010 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that results from TITAN, a 12-week study of SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol in African American patients with moderate to severe persistent asthma, showed significant improvement in lung function for patients taking SYMBICORT compared with those using budesonide alone.(1) Safety and efficacy results from the TITAN study(1,2) are...

2010-10-28 03:48:00

NEW YORK, Oct. 28 /PRNewswire/ -- See video from AstraZeneca at: http://www.thenewsmarket.com/CustomLink/CustomLinks.aspx?GUID=7c13a65b-0529-4b28-82e0-7ebe8b9d9f42&bhcp=1&alertid=226c94c1-b49b-45a9-b982-615158357500# Anglo-Swedish pharmaceutical company AstraZeneca announced that revenue for the third quarter declined by 2% at constant exchange rates (CER) to $7,898 million. Strong double-digit sales growth at CER for Crestor, Symbicort and Seroquel XR. Revenue in markets outside...